Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Dexamethasone 140Lenalidomide 60Bortezomib 56Calcium Dobesilate 48Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10isatuximab 9Cyclosporine 9pembrolizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Methylprednisolone Acetate × Plasma cell × Clear all
NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡